01—Abstract
Summary
Summary of the 10-K filed March 11, 1997. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 1996 results show a company growing sales and earnings at a steady clip while absorbing a major acquisition.
Net sales rose 10.0% to $11.01 billiona, driven by 11.5% volume growth, partially offset by a 1.6% drag from a stronger U.S. dollar. Net earnings increased 11.4% to $1.88 billion, and earnings per share rose to $2.41 from $2.12. Gross margin edged up to 57.0%, and the effective tax rate held at 29.5%.
The pharmaceutical and nutritional segment was the main growth engine, with sales up 12.0%, led by anti-infectives such as Biaxin and nutritionals such as Ensure and Similac. The key strategic event was the 1996 purchase of MediSense, Inc., a blood glucose self-testing company, for roughly $867 millionb in cash. The deal added goodwill and intangibles and carried a $37 million in-process R&D charge, which lifted R&D spending 12% to $1.2 billion (10.9% of sales).
Funding it pushed long-term debt up to $933 millionc from $435 million, and total assets rose to $11.1 billion. Liquidity remains strong, with AAA/Aa1 bond ratings, $1.5 billion in unused credit lines, and continued buybacks of about 58 million shares over three years. Investors should weigh the company's strong cash generation and consistent dividend growth against legal and regulatory exposure.
Abbott faces multiple antitrust suits covering infant formula and prescription drug pricing, as well as Superfund and other environmental claims. Management says none is expected to have a material adverse effect, but the Company also flags a looming Hytrin patent challenge from generics and growing pressure from managed care and government cost-containment efforts.
02—Key points
Key Highlights
- Net sales rose 10.0% to $11.01 billion in 1996, with volume gains of 11.5% and a 1.6% currency headwind.
- Net earnings grew 11.4% to $1.88 billion; EPS rose to $2.41 from $2.12 in 1995.
- Acquired MediSense, Inc. for about $867 million in cash, adding $635 million of intangibles and a $37 million in-process R&D charge.
- Long-term debt more than doubled to $933 million, while the company kept AAA/Aa1 bond ratings and $1.5 billion in unused credit lines.
- Pharmaceutical and nutritional segment sales grew 12.0% to $6.3 billion, led by anti-infectives (Biaxin) and adult nutritionals (Ensure).
- Significant litigation exposure remains, including 142 prescription drug pricing antitrust suits and infant formula antitrust cases, though management does not expect a material adverse effect.
- Shareholder returns were supported by rising dividends ($0.96 per share declared, up from $0.84) and roughly 58 million shares repurchased over three years.
03—Questions
Frequently Asked Questions
How did Abbott perform financially in 1996?
Abbott grew net sales 10.0% to $11.01 billion and net earnings 11.4% to $1.88 billion, with EPS of $2.41 versus $2.12 in 1995. Gross margin improved slightly to 57.0%, and the effective tax rate was steady at 29.5%.
What was the most significant corporate event in 1996?
The acquisition of MediSense, Inc., a blood glucose monitoring company, for about $867 million in cash. The purchase added diabetes-care products to the hospital and laboratory segment and was funded largely with new debt, including $250 million of 6.4% notes due 2006 and $250 million of 6.5% Eurodollar notes due 2001.
What are the main legal and regulatory risks?
Abbott faces numerous antitrust suits, including 142 cases over prescription drug pricing and infant formula pricing claims, plus environmental Superfund involvement at eleven sites. Government cost-containment measures, generic substitution, WIC rebates, and proposed user fees also pressure margins. Management believes none of these should have a material adverse effect on financial position or results.
How is Abbott's balance sheet and liquidity position?
Total assets reached $11.1 billion and shareholders' investment was $4.8 billion. Long-term debt rose to $933 million, and short-term borrowings were $1.38 billion. Operating cash flow was $2.38 billion, covering capital expenditures of $949 million and dividends of $728 million, and the company retained AAA and Aa1 ratings.
What products drive Abbott's revenue?
Anti-infectives (about $1.41 billion), adult nutritionals (about $1.23 billion), and infant formula (about $1.15 billion) each contributed more than 10% of consolidated sales. Key brands include Biaxin, Depakote, Ensure, Similac, and the hospital diagnostics and I.V. product lines.
04—Continue